October 15, 2014
Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis
Alpharetta, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis.
September 18, 2014
Clearside Biomedical, Inc. Completes $16 Million Series B Financing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside order tramadol online mastercard Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.
September 18, 2014
G1 Therapeutics Initiates Phase 1 Clinical Trial of G1T28-1
RESEARCH PARK TRIANGLE, NC, September 10, 2014 – G1 Therapeutics, Inc., a privately held, clinical-stage pharmaceutical company, today announced the initiation of a Phase 1 clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications.
September 4, 2014
Clearside Biomedical, Inc. Completes $16 Million Series B Financing
ALPHARETTA, Ga. – (BUSINESS WIRE) – Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.
August 19, 2014
Edison Partners Announces Investment in Clinverse, Inc.
LAWRENCEVILLE, N.J., Aug. 19, 2014 (GLOBE NEWSWIRE) — via PRWEB – Edison Partners proudly announced today leading a $9 million growth financing of Clinverse, Inc. Based in Durham, NC, Clinverse is an emerging leader in clinical trial finance, automating millions of dollars in financial transactions for clinical trials across the globe. Edison’s $5 million investment will accelerate the company’s product roadmap, bolster infrastructure, and expand sales and marketing. Co-investors include Hatteras Venture Partners.
June 17, 2014
G1 Therapeutics Completes Leadership Team with Appointment of Raj Malik, MD, Chief Medical Officer and Greg Mossinghoff, Chief Business Officer
RESEARCH PARK TRIANGLE, NC, June 17, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer.
May 20, 2014
G1 Therapeutics Appoints Dr. Mark Velleca as Chief Executive Officer
Research Triangle Park, NC, May 20, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced the appointment of Mark Velleca, M.D., Ph.D. as chief executive officer, effective immediately.
May 14, 2014
Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $4.8 million in seed funding.
April 21, 2014
Clinipace becomes a ‘preferred provider,’ starts acting like a big CRO
On April 9, Morrisville’s Clinipace Worldwide announced a partnership with Massachusetts pharmaceutical company Karyopharm Therapeutics (Nasdaq: KPTI), a development-stage company working primarily on cancer treatments. In this arrangement, Karyopharm chose Clinipace as a “preferred provider” in which Clinipace will manage several clinical programs, including oncology and wound healing.
March 12, 2014
Clinipace Worldwide Expands into Asia with Acquisition of Choice Pharma
MORRISVILLE, N.C. (Business Wire) March 11, 2014 – Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the closing of its merger with Choice Pharma, a Pan-Asian contract research organization. Bringing these organizations together strengthens Clinipace Worldwide’s operational and therapeutic expertise in Asia, a region in high demand by Clinipace’s clients.